Cleared for individuals aged 4 to 60 under the NDCT Rules, Takeda’s two-dose shot provides long-term protection against all four dengue serotypes without requiring prior infection testing.
Add businessleague.in as a Preferred Source
NEW DELHI — In a major victory for national public health, the Drug Controller General of India (DCGI) has granted regulatory approval for QDENGA, a tetravalent dengue vaccine developed by Takeda Biopharmaceuticals. Approved under the New Drugs and Clinical Trials (NDCT) Rules, 2019, the shot is indicated for individuals between 4 and 60 years of age.
QDENGA becomes the first dengue vaccine approved in India. Crucially, unlike earlier global vaccine generations, it can be safely administered regardless of an individual’s prior exposure to the virus—eliminating the need for complex pre-vaccination blood screening.
1. Why This Approval Matters for India
India carries nearly one-third of the global dengue burden. Rapid urbanization, monsoon pooling, and climate changes have turned the mosquito-borne viral disease into an endemic, year-round crisis.
🦟 The Disease Impact on India:
📊 113,000+ Reported Cases ➔ Official baseline data recorded in 2025 alone.
📉 Millions Unreported ➔ Epidemiological models estimate true infections in tens of millions annually.
🧬 Co-Circulating Serotypes ➔ All 4 viral strains (DEN-1, DEN-2, DEN-3, DEN-4) active simultaneously.
Because dengue lacks a targeted antiviral cure and can quickly progress to severe dengue hemorrhagic fever requiring intensive care, preventive vaccination marks a major structural shift in how healthcare systems handle seasonal surges.
2. Vaccine Profile & Clinical Performance
QDENGA is a tetravalent, live-attenuated vaccine designed to induce neutralizing antibodies against all four dengue virus serotypes. It has earned WHO pre-qualification and is already approved in 43 countries across Europe, Latin America, and Asia, with over 32 million doses distributed globally.
Key Clinical Trial Benchmarks (TIDES Phase III & DEN-302)
How the QDENGA Immunization Protocol Works
Executive Quote: “The latest seven-year data for QDENGA show continued protection against dengue infection and hospitalization across all four serotypes, an important milestone for communities and health systems,” stated Dr. Mahender Nayak, Head of Intercontinental Markets at Takeda. Following DCGI clearance, Takeda plans to work alongside public health agencies to rollout distribution frameworks across India.
Add businessleague.in as a Preferred Source
